Clinical Trials in Pittsburgh

Showing 8721-8740 of 21,047 trials

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04227275

Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.

Metastatic Castration-resistant Prostate Cancer

Tceleron Therapeutics, Inc.16 participantsStarted Nov 2019

Tampa, Florida, United States • Kansas City, Kansas, United States • St Louis, Missouri, United States +6 more locations

COMPLETEDPhase 377 miles

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

NCT02755597

This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.

Relapsed/Refractory Multiple Myeloma

AbbVie291 participantsStarted Jul 2016

Aurora, Colorado, United States • Aurora, Colorado, United States • Durham, North Carolina, United States +94 more locations

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Find Trials by Condition in Pittsburgh

Safety and Tolerability of Repeat Courses of IM Alefacept

BioVentrix Revivent TC™ System Clinical Study

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Study of Sargramostim in Patients With COVID-19

TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

A Dose Finding Study to Treat Bone Tumor(s)

TYRX™ Pocket Health Study

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite

Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome